Filing Flows › Health Care › Cronos Group (CRON)
Cronos Group (CRON) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Cronos Group (CRON) Q3 2026 earnings results →
Q3 2026 Revenue up 72% year over year to $83.9M · 16¢ of every $1 of revenue kept as net profit · operating margin 10.8%
Cronos Group made $83.9M in Q3 2026 (+72% Y/Y): Cannabis flower $48.0M, Other revenues $20.5M, Cannabis extracts $15.5M. Operating margin 10.8%, net earnings $13.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $83.9M in Q3 2026, up 72% year over year and up 19% from the previous quarter. Cannabis flower was the largest line at 57% of revenue. Cannabis flower added $21.6M year over year (up 82%), 62% of the total change.
Gross margin was 38.5%, up 0.9 points from Q3 2025. Operating profit was $9.0M, a 10.8% margin (up 11.8 points year over year). Operating expenses grew 23% against revenue growth of 72%. The fastest-growing cost line was Sales & marketing (+35%). Net earnings were $13.8M, down 47% year over year. The effective tax rate was 4.8%. Non-operating items added $9.7M, 52% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $34.3M (up 158% year over year), 193% of net income including minority interests. Non-cash charges added back $4.7M of depreciation and amortization and $2.3M of share-based compensation. Working capital and other items added $9.5M. Capital expenditures of $9.9M left free cash flow of $24.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $83.9M | +72% | 10.8% | $13.8M | $34.3M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $70.6M | +60% | 10.5% | $32.1M | $24.0M |
| Q1 2026 | 10-Q | May 11, 2026 | $59.0M | +41% | -3.1% | $15.7M | $10.9M |
| Q4 2025 | 10-K | Feb 26, 2026 | $58.4M | +42% | -12.8% | −$491K | $11.8M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $48.8M | +5% | -1.0% | $28.3M | $13.3M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $44.3M | +14% | -12.0% | −$38.5M | $2.8M |
| Q1 2025 | 10-Q | May 8, 2025 | $41.9M | +18% | -9.7% | $7.7M | −$2.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Cronos Group
Cronos is incorporated under the laws of the Province of British Columbia with principal executive offices located at 4491 Concession Rd 12, Stayner, Ontario L0M 1S0. The Company’s telephone number is +1-416-504-0004, the website is https://thecronosgroup.com/ and the investor relations section of the website is https://ir.thecronosgroup.com/. All references to Cronos’ website are inactive references, are for informational purposes only and are not intended to incorporate any information from or referenced on its website into this Annual Report.
In its own words, from its 10-K, filed Feb 26, 2026.
Cronos Group against its Medicinal Chemicals & Botanical Products peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +72% against the peers' median +7%. Operating margin: 10.8% against the peers' median 4.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CRON Cronos Group | Q3 2026 | $83.9M | +72% | 10.8% |
| CURLF Curaleaf Holdings | Q3 2026 | $353M | +11% | 0.8% |
| TLRY Tilray Brands | Q1 FY27 | $257M | +23% | -9.4% |
| TRLV Trulieve Cannabis | Q3 2026 | $230M | -20% | 18.5% |
| USNA Usana Health Sciences | Q2 2026 | $223M | -5% | -9.0% |
| AAWH Ascend Wellness Holdings | Q2 2026 | $126M | -0.9% | 4.2% |
| CGC Canopy Growth | Q2 FY27 | $71.1M | +20% | -23.1% |
| JUSH Jushi Holdings | Q3 2026 | $70.5M | +7% | 5.0% |
| BTMD biote | Q3 2026 | $43.3M | -10% | 5.7% |
Source: Cronos Group 10-Q on SEC EDGAR · CIK 1656472 · Medicinal Chemicals & Botanical Products
Guidance and outlook
13F: who owns CRON and who is buying
More on CRON
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results